Innately Curing Cancer
LIfT Biosciences is a biotech bringing to market a first-in-class 'off-the-shelf' innate cell therapy called Neutrophil based Leukocyte Infusion Therapy (N-LIfT). N-LIfT is the world's first neutrophil-based cancer therapeutic product that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with special cancer killing and immune recruitment capabilities, whilst additionally maintaining minimal damage to healthy cells.
Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for delivering complete remission in all solid tumours. Our planned Series A in 2021 will fund our manufacture scale-up and phase I/II orphan PoC trial is in some of the most challenging solid tumours e.g. Pancreatic (PDAC), Liver (HCC) and Lung (NSCLC).
LIfT BioSciences’ N-LifT therapy platform is an off-the-shelf allogeneic patented product that we mass-produce from exceptional stem cells from donors with exceptional immunity. The aim is to give cancer patients the exceptional innate immune system that these donors with no family history of cancer have, and to arm their own adaptive immune systems with the ability to attack the tumour in the future.
LIfT BioSciences are the industry leaders in neutrophil ATMPs (currently only), the team is made-up from a combination of experienced industry executives and world-class scientists and experts, such as Professor Zheng Cui of Wake Forrest University. LIfT has already proven to be 100% curative in mice and with promising human data in an FDA approved safety trial showing up to 80% tumour necrosis in a mix of late-stage carcinoma patients even at low dose.
We are currently completing pre-clinical work before running our first-in-human clinical trial. The aim is to demonstrate remission in high unmet need solid tumours by 2023, including pancreatic cancer.
The video below shows LIfT in action killing Cervical Cancer Cells:
Scientist in the Lab
Neutrophil in action
Edited Image 2016-07-04 13-47-24